Last reviewed · How we verify
Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (CATERPILLAR)
The goal of this assessor blinded randomized controlled trial is to compare a lock solution containing taurolidine, citrate and heparin to a heparin only lock solution for the prevention of central line associated bloodstream infections in paediatric oncology patients with a central venous access device.
Details
| Lead sponsor | Princess Maxima Center for Pediatric Oncology |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 462 |
| Start date | Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Central Line-associated Bloodstream Infection (CLABSI)
Interventions
- TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)
- Heparin lock (heparin 100 IU/mL)
Countries
Netherlands